EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update - Three patients treated with ZEVASKYN ® in Q1 2026 - -QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first quarter of 2026, one treatment to date in the second quarter, one biopsy currently in manufacturing process, and six additional patients expected to be biopsied in the second quarter, three of whom have biopsies scheduled. ──────────────────────────────────────────────────────────────────────────────────────────────────── Qualified treatment center (QTC) network expand…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Abeona Therapeutics Inc.
ABEONASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press release dated May 13, 2026 99.2 Abeona Therapeutics Inc.…
Company context
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Current securities
Historical securities (1)
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Filed exhibits (2)
EX-99.2
Open exhibit ↗